西塔格利酸通过调节巨细胞两极分化来改善糖尿病慢性炎症
Xiaoxia Hu1, Yalong Li1, Xinyue Liu1
1The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Frontiers in endocrinology
|April 22, 2025
概括
在2型糖尿病模型中,酸降低了炎症并改善了巨细胞的两极分化. 它调节mTORc1/PPAR-γ/NF-κB通路,为糖尿病并发症提供潜在的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 2型糖尿病的特点是慢性炎症和变化的巨细胞两极分化.
- 西塔格利普丁酸盐是一种用于治疗2型糖尿病的二二基化酶-4 (DPP-4) 抑制剂.
- 巨细胞两极分化在糖尿病并发症的发病过程中起着至关重要的作用.
研究的目的:
- 在2型糖尿病的小鼠模型中研究西塔格利普丁酸盐的抗炎作用和机制.
- 阐明西塔格利普丁酸盐在调节巨细胞极化中的作用.
- 探索涉及西塔格利普丁酸盐作用的潜在分子通路.
主要方法:
- 在体外研究中,使用Raw264.7细胞暴露于高葡萄糖和西塔格利普丁酸盐.
- 转录组分析以确定差异表达的基因.
- 在实体研究中,使用高脂肪饮食和链毒素诱导的2型糖尿病小鼠模型.
- 组织学分析和西部斑点来评估巨细胞两极分化和信号通路.
主要成果:
- 西塔格利普丁酸盐减少了高葡萄糖诱导的IL-6和TNF-α的分泌,同时通过增强巨细胞两极分化来增加IL-10的分泌.
- 在体内,酸治疗逆转了高血糖症,增加了体重,减少了内脏脂肪,改善了脂肪细胞和肝脂沉积.
- 西塔格利酸调节了mTORc1/PPAR-γ/NF-κB通路,减少了M1巨细胞标记物,增加了M2标记物.
结论:
- 西塔格利酸通过改善2型糖尿病中巨细胞极化失衡,产生抗炎作用.
- 该机制涉及对mTORc1/PPAR-γ/NF-κB信号通路的调制.
- 西塔格利普丁酸盐在治疗2型糖尿病的炎症和相关并发症方面显示出治疗潜力.
更多相关视频
07:45Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis
Published on: November 28, 2015
35.3K
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
25.1K
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
109
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
109
Glucagon-like Receptor Agonists
261
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
261
Inflammation
51.0K
Overview
51.0K
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
